Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New pharmacon allows testicular tumors to shrink

28.12.2016

A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies. In mice, the substance kills degenerated cells and allows testicular tumors to shrink. Researchers at the University of Bonn were able to demonstrate this in a recent study. However, first clinical trials are still pending. The work has now been published in the “Journal of Cellular and Molecular Medicine”.

Testicular cancer is the most common malignant tumor disease in men between 20 and 40 years of age. It can usually be treated well. In some cases, however, the cancer hardly responds or does not respond at all to treatment.


Prof. Hubert Schorle (left), Dr. Daniel Nettersheim (center) and PhD student Sina Jostes (right) investigate changes in gene expression following JQ1 treatment in testicular cancer cells.

Photo: Simon Schneider/Institute for Pathology/UKB

A substance that was originally destined to be an innovative contraceptive is offering new hope in these cases. An experimental drug with the cryptic name JQ1 blocks sperm maturation and was discussed to be a male contraceptive. Instead, it may be suitable for cancer therapy.

JQ1 belongs to a new class of drugs with far-reaching abilities: its members fundamentally influence which genes in the cell are active and which are not. The hereditary material DNA is similar to an extremely long strip of Morse code, on which the assembly instructions for the cellular molecules are found. To fit into the cell nuclei, this strip of Morse code is wrapped around small protein balls at regular intervals – the histones. Histones and DNA together resemble a string of pearls.

However, the histones do not only play a structural role. They also feature chemical tags – called methyl or acetyl groups. These tags signal to the synthesis machinery in the cell whether the strip of Morse code should be read at this point or not. “JQ1 inhibits those proteins that read these histone marks and thus changes the gene activity in the cell,” explains Prof. Hubert Schorle from the Institute for Pathology at the University of Bonn.

The cancer cells react very sensitive to these changes: they activate a suicide program, called apoptosis. “In a testicular cancer mouse model, the tumors began to shrink after administering JQ1,” explains the lead author of the study, Sina Jostes. “In contrast, healthy skin cells seem to tolerate JQ1 very well.”

Especially effective in combination

Besides JQ1, other drugs that alter the marks of the histones are also known. One of these is romidepsin. The laboratory in Bonn was recently able to show that romidepsin is also very effective at fighting testicular cancer cells. Unlike JQ1, romidepsin is already approved for the treatment of patients with certain types of cancer.

“In our study, we treated mice with both JQ1 and romidepsin,” explains Dr. Daniel Nettersheim, who helped in planning and performing the studies. “This way, we achieved a similar effect alike JQ1 or romidepsin treatment alone, but we could reduce the quantities of both substances. Such a combination therapy to treat testicular tumors may be much better tolerated. Chemotherapy-resistant patients could also benefit from this.” However, clinical studies are now needed to move the treatment towards the clinics.

Besides scientists from the University of Bonn, the studies also involved researchers from the University of St. Gallen (Switzerland) and Harvard Medical School (USA).

Publications:

Sina Jostes, Daniel Nettersheim, Martin Fellermeyer, Simon Schneider, Francois Hafezi, Friedemann Honecker, Valerie Schumacher, Matthias Geyer, Glen Kristiansen and Hubert Schorle: The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo; Journal of Cellular and Molecular Medicine; DOI: 10.1111/jcmm.13059

Daniel Nettersheim, Sina Jostes, Martin Fabry, Friedemann Honecker, Valerie Schumacher, Jutta Kirfel, Glen Kristiansen and Hubert Schorle: A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment; Oncotarget; DOI: 10.18632/oncotarget.11647

Media contact:

Prof. Hubert Schorle
Institute of Pathology
University of Bonn
Telephone: +49 (0)228/28716342
E-mail: hubert.schorle@ukb.uni-bonn.de

Dr. Andreas Archut | idw - Informationsdienst Wissenschaft

More articles from Health and Medicine:

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

nachricht Pain: Perception and motor impulses arise in the brain independently of one another
12.12.2018 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

New discoveries predict ability to forecast dementia from single molecule

12.12.2018 | Health and Medicine

CCNY-Yale researchers make shape shifting cell breakthrough

12.12.2018 | Physics and Astronomy

Pain: Perception and motor impulses arise in the brain independently of one another

12.12.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>